Clinical Trial Update: A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care [Phase 3]

View source ↗

Summary

A phase 3 trial comparing azacitidine to conventional care in high-risk myelodysplastic syndromes has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Conventional care

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2010-07-05